Imagine watching your body betray you, muscles twisting uncontrollably, movements becoming a struggle. This is the harsh reality for those living with X-linked dystonia-parkinsonism (XDP), a rare and devastating movement disorder that primarily affects men of Filipino descent. But here's where it gets even more heartbreaking: diagnosing XDP has been notoriously difficult, leaving many sufferers in a diagnostic limbo.
Researchers at Brigham and Women's Hospital and Harvard Medical School have developed a groundbreaking genetic test that promises to change this. Presented at the Association for Molecular Pathology (AMP) 2025 Annual Meeting & Expo in Boston (https://amp25.amp.org/), this test targets the elusive genetic culprit behind XDP, offering hope for faster and more accurate diagnoses.
XDP mimics Parkinson's disease, causing muscle spasms, tremors, and abnormal postures, often starting in the face, jaw, or neck. As the disease progresses, it robs individuals of their independence, making speech, walking, and daily activities increasingly challenging. Early diagnosis is crucial, as it allows patients to access support, plan their care, and receive appropriate genetic counseling.
And this is the part most people miss: Diagnosing XDP is complicated because its symptoms overlap with other neurological disorders. The key lies in a specific region of the TAF1 gene, harboring subtle DNA changes called disease-specific single nucleotide changes (DSCs). These DSCs are often overlooked by standard genetic tests, leaving many cases undiagnosed.
Led by Dr. Eirini Christodoulou, a clinical fellow in pathology at Harvard University and a laboratory genetics and genomic fellow at Brigham and Women's Hospital, the research team designed a test that sequences three critical DSCs associated with XDP. They validated its accuracy by testing eight individuals known to have the mutation, seven without it, and three suspected cases.
The results were remarkable. The test accurately identified all positive cases and correctly diagnosed the three suspected individuals, two of whom had previously received negative results from standard genetic testing.
"Our test uncovers cases that routine sequencing methods like exome sequencing and panel testing have missed," Dr. Christodoulou explained. "We aim to end the diagnostic odyssey for patients whose symptoms overlap with other movement disorders."
XDP, also known as Lubag disease, is an X-linked disorder, meaning it’s caused by changes on the X chromosome. This is why it disproportionately affects males, who have only one X chromosome. Females, with two X chromosomes, can often compensate for the mutation, making them carriers without developing the full syndrome, though some may experience mild symptoms.
While there’s no cure for XDP, medications can manage movement and muscle symptoms, and some patients benefit from deep brain stimulation. Physical, speech, and occupational therapy are essential components of care plans.
Here’s where it gets controversial: The mutation is believed to have originated generations ago and is strongly linked to families from the Philippine island of Panay. However, limited awareness among clinicians outside Filipino communities contributes to underdiagnosis.
The study authors emphasize the importance of including this new test in the diagnostic process for individuals suspected of having XDP. "This could increase diagnosis rates and reduce the costs associated with prolonged diagnostic journeys," they wrote in their abstract.
But what do you think? Is enough being done to raise awareness about XDP, especially among non-Filipino clinicians? Should this test be more widely available, even in regions with lower prevalence? Let us know your thoughts in the comments below.
Provided by the Association for Molecular Pathology
Citation: New genetic test targets elusive cause of rare movement disorder (2025, November 15) retrieved 15 November 2025 from https://medicalxpress.com/news/2025-11-genetic-elusive-rare-movement-disorder.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
